Read more
9:51 PM ยท 6 December 2024

US100 gains 0.8% ๐Ÿ“ˆ Meta Platforms leads BigTech gains; Lululemon surges 18%

US100
Indices
-
-
Palantir
Stocks
PLTR.US, Palantir Technologies Inc - class A
-
-
Lululemon
Stocks
LULU.US, Lululemon Athletica Inc
-
-

Wall Street extends gains on Friday with US100 0.8% higher; Alphabet 9GOOGL.US) and Meta Platforms (META.US) lead gains among BigTech's. The 10-year US treasury yields are slightly lower today, now at 4.16%. 

  • Software sector still on the rise; AppLovin (APP.US) surges 9%. Oracle (ORCL.US) and Adobe (ADBE.US) shares gain 2.5%
  • Palantir (PLTR.US) shares gain 6% to new all-time high after Booz Allen Hamilton partnership on US Defence sector capabilities
  • Smith & Wesson (SWBI.US) plunges 17% as company informed that inflation hurts firearms sales; adjusted profit falls
  • UoM sentiments above expectations (however Expectations subindex lower than expected); short term inflation expectations higher (2.9% vs 2.7% exp.)
  • NFP report points to lower private payrolls; slightly higher than expected US unemployment rate and higher than expected wage growth 
  • Fed members comments point to rate cut on December or January meeting; however, a scale of rate cuts in 2025 may be less than markets anticipate
Source: xStation5

Falling oil and natural gas prices pressure energy fuels sector. Weaker sentiments across healthcare and insurance stocks. IT Services, Software and other tech sectors lead Wall Street today. Source: xStation5

US Macro

US Non-farm Payrolls (November): 227k (Forecast 220k, Previous 12k)

  • Private payrolls:194k v 205k exp. and -28k previously
  • Manufacturing payrolls: 22k vs 30 exp. and -46k previously

Unemployment rate: 4.2% vs 4.1% exp. and 4.1% previously

  • US average earnings YoY: 4% vs 3.9% exp. and 4% previously
  • US average earnings MoM: 0.4%vs 0.3% exp. and 0.4% previously
  • US Average workweek hours: 34.3 vs 34.3 exp. and 34.3 previously

University of Michigan consumer sentiments report (prelim) came in 74 vs 73.2 and 71.8 previously

  • Expectations: Actual 71.6 (Forecast 77.7, Previous 76.9)
  • Condition Prelim: 77.7 (Forecast 65.2, Previous 63.9)

University Michigan 1 Yr Inflation Prelim Actual 2.9% (Forecast 2.7%, Previous 2.6%)

  • University Michigan 5 Yr Inflation Prelim Actual 3.1% (Forecast 3.1%, Previous 3.2%)

Buyers dominate session on Wall Street again.

 

Source: xStation5

Lululemon surges after Q3 earnings

Retail company Lululemon (LULU.US) Q3 2024 revenue came in at $2.4 billion vs $2.2 billion reported a year ago, above $2.36 billion expected by Bloomberg analysts. Earnings came in above estimates of $2.75 a share, at $2.87 level; well above $2.53 EPS presented in Q3 2023. Lululemon expects that Q4 revenue of $3.48 billion-$3.51 billion will be almost in line with consensus estimates of $3.5 billion.

Lululemon sees Q4 EPS between $5.56 and $5.64, below estimates of $5.70. The retailer boosted a full-year revenue guidance to between $10.45 billion and $10.49 billion, up from the $10.38 billion-$10.48 previously. Projected EPS came in $14.08-$14.16 vs $13.95-$14.15 expected previously. Gross margins came in 1.5 p.p. higher at 58.5% vs 0.8 p.p. in Q2 2024. The company approved a $1 billion buyback program, effective since December 3. Also, Nike (NKE.US) shares gains almost 2% today.

 

Source: xStation5

A leading US gun maker, Smith&Wesson (SWBI.US) reported second-quarter fiscal 2025 adj. net income at $4.8 million ($0.11 per share) vs $6.5 million, a year ago ($0.14 per share). Revenue rose by 3.8% year-over-year to $129.7 million. The company informed that results are below its expectations, because of softer demand trends, pressured by higher inflation. Smith & Wesson lowered the expectations, with revenues lower 10 to 15% than in fiscal 2024. 

Smith&Wesson shares (D1 interval)

 

Source: xStation5

15 December 2025, 10:49 PM

Daily Summary: Tech sector fears send markets lower

15 December 2025, 9:05 PM

End of Zillow? Google enters another market.

15 December 2025, 6:53 PM

US OPEN: Mild optimism at the start of the week

15 December 2025, 1:50 PM

Sanofi Under Pressure After FDA Delay and Failed Trials

The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.

Join over 2 000 000 investors from around the world